{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:51:55Z","timestamp":1770436315169,"version":"3.49.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oral Oncology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.oraloncology.2012.05.005","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T21:02:26Z","timestamp":1339534946000},"page":"991-996","source":"Crossref","is-referenced-by-count":32,"title":["Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: Potentials as therapeutic target"],"prefix":"10.1016","volume":"48","author":[{"given":"Till Sebastian","family":"Clauditz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Gontarewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Lebok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Christina","family":"Tsourlakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias J.","family":"Grob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"M\u00fcnscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainald","family":"Knecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waldemar","family":"Wilczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oraloncology.2012.05.005_b0005","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"New Engl J Med"},{"issue":"Suppl. 4","key":"10.1016\/j.oraloncology.2012.05.005_b0010","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0015","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF00718645","article-title":"Immunohistochemical expression of epidermal growth factor receptor in salivary gland tumours","volume":"415","author":"Yamada","year":"1989","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0020","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/bjc.1989.156","article-title":"Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival","volume":"59","author":"Dazzi","year":"1989","journal-title":"Br J Cancer"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0025","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1200\/JCO.1997.15.8.2858","article-title":"Immunocytochemical markers in stage I lung cancer: relevance to prognosis","volume":"15","author":"Pastorino","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0030","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1556-0864(15)30414-7","article-title":"Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib","volume":"1","author":"Clark","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0035","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1200\/JCO.2010.31.8923","article-title":"American society of clinical oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy","volume":"29","author":"Keedy","year":"2011","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0040","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","article-title":"Critical update and emerging trends in epidermal growth factor receptor targeting in cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1746-1596-4-36","article-title":"Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer","volume":"4","author":"Casorzo","year":"2009","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0050","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/dji112","article-title":"Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer","volume":"97","author":"Cappuzzo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0055","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1200\/JCO.2007.14.8924","article-title":"Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21","volume":"26","author":"Zhu","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0060","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s00292-009-1141-4","article-title":"EGFR mutation analysis in non-small-cell lung cancer: experience from routine diagnostics","volume":"30","author":"Tapia","year":"2009","journal-title":"Pathologe"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0065","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1200\/JCO.2005.02.857","article-title":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib","volume":"23","author":"Eberhard","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0070","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0080","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0090","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0095","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1513\/pats.200809-107LC","article-title":"KRAS mutations in non-small cell lung cancer","volume":"6","author":"Riely","year":"2009","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0100","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0105","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/annonc\/mdi006","article-title":"Impact of EGFR expression on colorectal cancer patient prognosis and survival","volume":"16","author":"Spano","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0115","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2559.2010.03643.x","article-title":"Homogeneous EGFR amplification defines a subset of aggressive Barrett\u2019s adenocarcinomas with poor prognosis","volume":"57","author":"Marx","year":"2010","journal-title":"Histopathology"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0120","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1158\/1078-0432.CCR-07-1257","article-title":"Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer","volume":"13","author":"Schlomm","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0125","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/modpathol.3800575","article-title":"Epithelial growth factor receptor status in primary and recurrent ovarian cancer","volume":"19","author":"Stadlmann","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0130","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0135","series-title":"Pathology and Genetics of Head and Neck Tumours","author":"Barnes","year":"2005"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0140","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.joms.2005.03.006","article-title":"Management and outcome of patients with malignant salivary gland tumors","volume":"63","author":"Bell","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0145","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.oraloncology.2009.05.635","article-title":"Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0150","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/00005537-200108000-00011","article-title":"Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands","volume":"111","author":"Gibbons","year":"2001","journal-title":"Laryngoscope"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0155","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/hed.10104","article-title":"Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin","volume":"24","author":"Vered","year":"2002","journal-title":"Head Neck"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0160","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1067\/moe.2003.40","article-title":"Immunohistochemical detection of epidermal growth factor and its receptor in salivary gland carcinomas","volume":"95","author":"Katopodi","year":"2003","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0165","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/hed.21052","article-title":"Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib","volume":"31","author":"Vidal","year":"2009","journal-title":"Head Neck"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0170","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1158\/1078-0432.CCR-09-0238","article-title":"Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance","volume":"16","author":"Williams","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0175","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.bjc.6604875","article-title":"Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas","volume":"100","author":"Dahse","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0180","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2007.11.8612","article-title":"Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and\/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands","volume":"25","author":"Agulnik","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0185","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.oraloncology.2008.07.010","article-title":"Cetuximab in recurrent and\/or metastatic salivary gland carcinomas: a phase II study","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0190","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/1097-0142(19920415)69:8<2021::AID-CNCR2820690803>3.0.CO;2-7","article-title":"Mucoepidermoid carcinoma of intraoral salivary glands. Evaluation and application of grading criteria in 143 cases","volume":"69","author":"Auclair","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0195","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nm0798-844","article-title":"Tissue microarrays for high-throughput molecular profiling of tumor specimens","volume":"4","author":"Kononen","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0200","first-page":"1901","article-title":"Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer","volume":"25","author":"Merseburger","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0205","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1525-1578(10)60569-7","article-title":"Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas","volume":"7","author":"Pan","year":"2005","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0210","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.oraloncology.2009.01.013","article-title":"KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas","volume":"45","author":"Dahse","year":"2009","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0215","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/sj.bjc.6604430","article-title":"Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma","volume":"99","author":"Dahse","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0220","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0225","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0230","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/CCO.0b013e32833500d2","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer","volume":"22","author":"Rosell","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0235","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1158\/1078-0432.CCR-09-0391","article-title":"Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations","volume":"15","author":"Morita","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0240","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0245","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1002\/cncr.25214","article-title":"Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor\u2013tyrosine kinase inhibitors","volume":"116","author":"Cohen","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0250","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0255","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.1167.11.3","article-title":"The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers","volume":"11","author":"Tokumo","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0260","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1634\/theoncologist.12-1-90","article-title":"Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing","volume":"12","author":"Sequist","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0265","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.oraloncology.2006.12.012","article-title":"Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy","volume":"43","author":"Milano","year":"2007","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0270","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/PAP.0b013e3181a9d4ed","article-title":"KRAS mutation testing in colorectal cancer","volume":"16","author":"Plesec","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0275","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1756-8722-2-9","article-title":"Updates in gastrointestinal oncology \u2013 insights from the 2008 44th annual meeting of the American society of clinical oncology","volume":"2","author":"Javle","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0280","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1200\/JCO.2005.01.2823","article-title":"Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a southwest oncology group study","volume":"23","author":"Hirsch","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0285","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1200\/JCO.2005.01.0793","article-title":"Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer","volume":"23","author":"Takano","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0290","first-page":"2623","article-title":"Expression of c-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study","volume":"15","author":"Shintani","year":"1995","journal-title":"Anticancer Res"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0295","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<439::AID-CNCR3>3.0.CO;2-K","article-title":"Basal cell adenocarcinoma of the salivary glands: comparison with basal cell adenoma through assessment of cell proliferation, apoptosis, and expression of p53 and bcl-2","volume":"82","author":"Nagao","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0300","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2559.2008.03159.x","article-title":"Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas","volume":"53","author":"Ettl","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0305","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1600-0714.2009.00770.x","article-title":"Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours","volume":"38","author":"Monteiro","year":"2009","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0310","first-page":"83","article-title":"Prognostic significance of EGFR, p53 and E-cadherin in mucoepidermoid cancer of the salivary glands: a retrospective case series","volume":"55","author":"Hoyek-Gebeily","year":"2007","journal-title":"J Med Liban"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0315","first-page":"435","article-title":"Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: possible implications for targeted therapy","volume":"19","author":"Shang","year":"2008","journal-title":"Oncol Rep"},{"issue":"26","key":"10.1016\/j.oraloncology.2012.05.005_b0320","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1200\/JCO.2010.34.4929","article-title":"A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer","volume":"29","author":"Hirsch","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oraloncology.2012.05.005_b0325","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1309\/AJCPST1CTHZS3PSZ","article-title":"EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry","volume":"133","author":"Sholl","year":"2010","journal-title":"Am J Clin Pathol"}],"container-title":["Oral Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368837512001601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368837512001601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T08:48:56Z","timestamp":1714034936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368837512001601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1368837512001601"],"URL":"https:\/\/doi.org\/10.1016\/j.oraloncology.2012.05.005","relation":{},"ISSN":["1368-8375"],"issn-type":[{"value":"1368-8375","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}